

Mutations in the TGF β Binding-Protein-Like Domain 5 of *FBN1* Are Responsible for Acromicric and Geleophysic Dysplasias

Carine Le Goff,¹ Clémentine Mahaut,¹ Lauren W. Wang,² Slimane Allali,¹ Avinash Abhyankar,³ Sacha Jensen,⁴ Louise Zylberberg,⁵ Gwenaëlle Collod-Beroud,^{6,7} Damien Bonnet,⁸ Yasemin Alanay,⁹ Angela F. Brady,¹⁰ Marie-Pierre Cordier,¹¹ Koen Devriendt,¹² David Genevieve,¹³ Pelin Özlem Simsek Kiper,⁹ Hiroshi Kitoh,¹⁴ Deborah Krakow,¹⁵ Sally Ann Lynch,¹⁶ Martine Le Merrer,¹ André Mégarbane,¹⁷ Geert Mortier,¹⁸ Sylvie Odent,¹⁹ Michel Polak,²⁰ Marianne Rohrbach,²¹ David Sillence,²² Irene Stolte-Dijkstra,²³ Andrea Superti-Furga,²⁴ David L. Rimoin,²⁵ Vicken Topouchian,²⁶ Sheila Unger,²⁴ Bernhard Zabel,²⁷ Christine Bole-Feysot,²⁸ Patrick Nitschke,²⁹ Penny Handford,⁴ Jean-Laurent Casanova,^{3,30} Catherine Boileau,³¹ Suneel S. Apte,² Arnold Munnich,¹ and Valérie Cormier-Daire^{1,*}

Geleophysic (GD) and acromicric dysplasia (AD) belong to the acromelic dysplasia group and are both characterized by severe short stature, short extremities, and stiff joints. Although AD has an unknown molecular basis, we have previously identified *ADAMTSL2* mutations in a subset of GD patients. After exome sequencing in GD and AD cases, we selected *fibrillin 1* (*FBN1*) as a candidate gene, even though mutations in this gene have been described in Marfan syndrome, which is characterized by tall stature and arachnodactyly. We identified 16 heterozygous *FBN1* mutations that are all located in exons 41 and 42 and encode TGF β -binding protein-like domain 5 (TB5) of *FBN1* in 29 GD and AD cases. Microfibrillar network disorganization and enhanced TGF β signaling were consistent features in GD and AD fibroblasts. Importantly, a direct interaction between *ADAMTSL2* and *FBN1* was demonstrated, suggesting a disruption of this interaction as the underlying mechanism of GD and AD phenotypes. Although enhanced TGF β signaling caused by *FBN1* mutations can trigger either Marfan syndrome or GD and AD, our findings support the fact that TB5 mutations in *FBN1* are responsible for short stature phenotypes.

Introduction

Geleophysic dysplasia (GD, [MIM 231050]) and acromicric dysplasia (AD, [MIM 102370]) belong to the acromelic dysplasia group and are both characterized by severe short stature (<−3 standard deviations [SD]), short hands and feet, joint limitations, and skin thickening.¹ Radiological manifestations include delayed bone age, cone-shaped epiphyses, shortened long tubular bones, and ovoid vertebral bodies. GD is distinct from AD because it has an autosomal-recessive mode of inheritance, characteristic facial

features—a “happy” face with full cheeks, a shortened nose, hypertelorism, a long and flat philtrum, and a thin upper lip—a progressive cardiac valvular thickening often leading to an early death, toe walking, tracheal stenosis, respiratory insufficiency, and lysosomal-like storage vacuoles in various tissues. AD has an autosomal-dominant mode of inheritance and is characterized by distinct facial features—a round face, well-defined eyebrows, long eyelashes, a bulbous nose with anteverted nostrils, a long and prominent philtrum, and thick lips with a small mouth—a hoarse voice, a pseudomuscular build, and

¹Department of Genetics, Université Paris Descartes, Unité Institut National de la Santé et de la Recherche Médicale (INSERM) U781, Hôpital Necker Enfants Malades, 75015 Paris, France; ²Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA; ³St. Giles Lab of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065, USA; ⁴Department of Biochemistry, University of Oxford, South Parks Rd, Oxford OX1 3QU, UK; ⁵Centre National de la Recherche Scientifique (CNRS) UMR71 93, Université Pierre et Marie Curie, 75005 Paris, France; ⁶INSERM, U827, 34000 Montpellier, France; ⁷Université Montpellier 1, UFR Médecine, 34000 Montpellier, France; ⁸Centre de Référence Malformations Cardiaques Complexes-M3C, Hôpital Necker-Enfants Malades, Université Paris Descartes, 75015 Paris, France; ⁹Pediatric Genetics Unit, Department of Pediatrics, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey; ¹⁰North West Thames Regional Genetics, Northwick Park Hospital, Harrow HA1 3UJ, UK; ¹¹Service de Génétique, Groupement Hospitalier Est, HFME, 69677 Bron, France; ¹²Center for Human Genetics, Catholic University of Leuven, 3000 Leuven, Belgium; ¹³Department of Medical Genetics, Université Montpellier 1, INSERM U844, 34000 Montpellier, France; ¹⁴Department of Orthopaedic Surgery, Nagoya University School of Medicine, Nagoya, Aichi 466-8550, Japan; ¹⁵Departments of Orthopedic Surgery and Human Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90068, USA; ¹⁶National Centre for Medical Genetics, Our Lady's Childrens Hospital, Crumlin, Dublin 12, Ireland; ¹⁷Unité de Génétique Médicale, Université Saint Joseph, Beirut 1104 2020, Lebanon; ¹⁸Department of Medical Genetics, Antwerp University and Hospital, 2650 Edegem, Belgium; ¹⁹Service de Génétique Clinique, Hôpital Sud, Université Rennes 1, UMR6061, 35200 Rennes, France; ²⁰Endocrinologie Gynécologie Diabétologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Hôpital Necker Enfants Malades, 75015 Paris, France; ²¹Division of Metabolism, Connective Tissue Unit, University Children's Hospital, 8032 Zurich, Switzerland; ²²Academic Department of Medical Genetics, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; ²³Department of Genetics, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; ²⁴Departments of Pediatrics and Human Genetics, University of Lausanne, 1015 Lausanne, Switzerland; ²⁵Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; ²⁶Department of Pediatric Orthopedic Surgery, Necker Hospital, 75015 Paris, France; ²⁷Centre for Pediatrics and Adolescent Medicine, Freiburg University Hospital, University of Freiburg, 79106 Freiburg, Germany; ²⁸Plateforme Génomique, Fondation Imagine Hôpital Necker Enfants Malades, 75015 Paris, France; ²⁹Plateforme de Bioinformatique, Université Paris Descartes, 75015 Paris, France; ³⁰Lab of Human Genetics of Infectious Diseases, Necker branch, University Paris Descartes and INSERM U980, Necker Medical School, 75015 Paris, France; ³¹INSERM U698, Bichat Claude Bernard, Université Paris Diderot, and Laboratoire de Biochimie et de Génétique Moléculaire, Hôpital Ambroise Paré, AP-HP, 92100 Boulogne, France

*Correspondence: valerie.cormier-daire@inserm.fr

DOI 10.1016/j.ajhg.2011.05.012. ©2011 by The American Society of Human Genetics. All rights reserved.

distinct skeleton features, including an internal notch of the femoral head, an internal notch of the second metacarpal, and the external notch of the fifth metacarpal.^{2,3}

We recently identified *ADAMTSL2* [MIM 612277] mutations in GD and demonstrated a direct involvement of *ADAMTSL2* in TGF β bioavailability.⁴ However, the absence of *ADAMTSL2* mutations in 19 out of 33 GD patients suggests genetic heterogeneity.⁵ The molecular etiology of AD has not been previously reported. The aim of our study was to identify (1) the gene mutated in AD and (2) an additional mutated gene in GD by studying those GD cases without *ADAMTSL2* mutations.

Subjects and Methods

Patients

Nineteen GD cases were included in the study, and they all fulfilled the diagnostic criteria, namely short stature <-3 SD, short hands and feet, restricted joint mobility, characteristic facial features, and progressive cardiac involvement (Table 1, Figure 1). Ten AD cases, including two familial cases, were included in the study. They all fulfilled the diagnostic criteria for AD, namely severe short stature, short hands and feet, progressively stiff joints, and characteristic facial features (Table 1, Figure 1). We collected blood samples from affected individuals after obtaining written informed consent, in accordance with the ethical standards of our institutional review board on human experimentation.

Exome Sequencing

Enrichment was performed by hybridization of shotgun fragment libraries to Agilent SureSelect in solution capture assays. Using the Solid3.5 (Life Technologies), we generated an average of 5.1 Gb of mappable sequence data per sample to achieve more than 40 \times median coverage of the targeted exome (38 Mb, ~18,000 genes). We first focused our exome analyses on nonsynonymous variants. We also defined variants as previously unidentified if they were absent from control populations and all datasets, including dbSNP129, the 1000 Genomes Project, and in-house exome data.

Mutation Detection

We designed a series of 66 intronic primers to amplify the 65 coding exons of *FBN1* (MIM 134797; NM_000138.4). We purified the amplicons and sequenced them by using the fluorescent dideoxy-terminator method on an automatic sequencer (ABI 3100).

Immunofluorescence

Skin fibroblasts from affected individuals and controls were obtained after written informed consent, in accordance with the ethical standards of our institutional review board on human experimentation and were grown in cell-culture chambers and fixed in 4% paraformaldehyde (PFA). After being blocked with 3% bovine serum albumin (BSA), cells were incubated with *FBN1* antibody (Millipore) overnight at 4°C, and followed by incubation with fluorescein-isothiocyanate-conjugated secondary antibodies at room temperature.

Immunoblotting Analysis

For pSMAD2 immunoblotting, cell lysates were obtained from skin fibroblasts (controls and GD and AD patients) and actin

(Invitrogen) and pSMAD2 (Cell signaling technology) antibodies were used. Respective protein species were quantified by densitometry (Kodak 1D image analysis software).

ELISA Assays for Active and Total TGF- β 1

TGF- β 1 present in 100 μ l culture medium of confluent fibroblasts from two affected individuals and unaffected controls was quantitated with the TGF- β 1 EMax Immunoassay kit (Promega). The samples were acidified for measurement of total TGF- β 1 (active plus latent). TGF- β 1 standard curves were undertaken for each assay. All experiments were performed in triplicate. A t test was performed.

Production of Recombinant Fibrillin-1 Peptide and BIAcore Analysis

We used a full-length human fibrillin-1 expression plasmid⁶ to generate hFib1-49, a fragment encoding residues 1–1525 (N-terminal half of fibrillin-1). The conditioned medium of the stably transfected HEK293F cells was used to purify hFib1-49 via Ni²⁺-agarose chromatography, essentially as previously described.⁷ Purified hFib1-49 in 10 mM sodium acetate (pH 4.5) was immobilized on a BIAcore CM5 sensor chip (research grade) with the amine coupling kit according to the manufacturer's instructions (chip and kit from GE Health Care, Piscataway, NJ). The Resonance unit coupled to the chip was 1614 RU, and the analysis used a BIAcore 3000 instrument (GE Health Care, Piscataway, NJ). The kinetic analysis was performed at 25°C in 10 mM HEPES buffer (pH 7.4) with 0.15 M NaCl, 2 mM CaCl₂, and 0.005% (v/v) surfactant P20 at a flow rate of 20 μ l/min. The purified mouse *Adamtsl2* was diluted in the above buffer at different concentrations and injected both to an uncoupled control flow cell and the cell coupled with hFib1-49. The sample injection time was 2 min and was followed by a pause of 6 min for dissociation. A total of 10 μ M NaOH solution was used for regeneration after each injection at a flow rate of 50 μ l/min for 30 s. The stabilization time after regenerations was 3 min. All the data were corrected with reference to the background binding in the control flow cell. We calculated the kinetic constants by assuming a 1:1 (Langmuir) binding model with the BIAevaluation software (version 4.0.1, GE Health Care, Piscataway, NJ).

Homology Modeling

Homology modeling of the cbEGF-TB5-cbEGF25 region was carried out with the coordinates of the fibrillin-1 cbEGF22-TB4-cbEGF23 structure (PDB 1UZJ) and Modeler software.⁸ Figures were rendered with the PyMOL Molecular Graphics System (Schrödinger).

Results

Exome Analysis

Among the 19 GD cases with no *ADAMTSL2* mutations, absence of consanguinity or recurrence in sibs prompted us to perform exome sequencing in two out of 19 unexplained GD cases. We also performed exome sequencing in three out of ten AD unrelated patients. We first focused our analyses on nonsynonymous variants, splice acceptor and donor site mutations, and coding indels because we anticipated that synonymous variants were far less likely to be pathogenic. We also defined variants as previously

Table 1. Clinical Manifestations of GD and AD Patients

Family	Origin	Diagnosis	Age (Years)	Height	Cardiac Involvement	Other
1	Belgium	GD	Death at 9	<-6 SD (80 cm)	mitral stenosis and insufficiency	tracheotomy at 3
2	France	GD	18	<-6 SD (112 cm)	mitral stenosis	HTAP, respiratory insufficiency, hepatomegaly, laryngeal stenosis
3	Russia	GD	12	<-6 SD (106 cm)	no	hepatomegaly
4	Switzerland	GD	21	<-6 SD (116 cm)	tricuspid stenosis, mild aortic insufficiency	
5	Russia	GD	8	-4 SD (103.5 cm)	no	
6	France	GD	5.7	-4 SD (97 cm)	no	laryngeal and respiratory insufficiency
7	U.K.	GD	Death at 3	-5 SD (75 cm)	no	respiratory insufficiency, HTAP, Sleep apnea
8	Turkey	GD	4.5	-4 SD (85 cm)	mitral and tricuspid stenosis	respiratory insufficiency, hepatomegaly, spleen apnea
9	Algeria	GD	Death at 4	<-6 SD (60 cm)	mitral and tricuspid stenosis	laryngeal and respiratory insufficiency, HTAP
10	Lebanon	GD	14	-3.5 SD (133 cm)	no	-
11	USA	GD	?	?	no	pyloric stenosis
12	Turkey	GD	3	-3 SD (85 cm)	no	
13	Russia	GD	18	-4 SD (134 cm)	mitral valve prolapse	
14	Iraq	GD	11	<-6 SD (92 cm)	yes	hepatomegaly
15	USA	GD	?	?	aortic stenosis, mitral and aortic valve insufficiencies	
16	Japan	GD	9	-6 SD (98 cm)	no	-
17	Australia	GD	3	-4 SD (76 cm)	severe pulmonary hypertension	hepatomegaly
18	USA	GD	?	?		
19	Korea/Japan	GD	7	-6 SD (88 cm)	mitral insufficiency	HTAP
20	France	AD	10	-6 SD (99 cm)	no	-
21	France	AD	62	-6 SD (125 cm)	no	broncho-pulmonary infection
22-a	France	AD	10	-3 SD (121 cm)	no	
22-b	France	AD	13	-3.5 SD (128 cm)	no	
22-c	France	AD	40	-6 SD (128 cm)	no	mother of 22 a and 22b
23	Belgium	AD	14	<-6 SD (111 cm)	no	broncho-pulmonary infection
24	Netherlands	AD	36	<-6 SD (119cm)	no	carpal tunnel syndrome, laminectomy C1-C3 for cervical spine stenosis
25	France	AD	13	<-6 SD (104cm)	no	
26	Italy	AD	43	<-6 SD (129cm)	no	
27-a	China	AD	10	-4 SD (117 cm)	no	
27-b	China	AD	35	-5 SD (130 cm)	no	mother of 27a
28	France	AD	54	<-6 SD 125 cm	no	carpal tunnel syndrome
29	France	AD	33	-6 SD (125 cm)	no	asthma

unidentified if they were absent from control populations and from all datasets including dbSNP129, the 1000 Genomes Project, and in-house exome data.

Considering the recessive mode of inheritance of GD, we selected 11 candidate genes on the basis of the presence of

either two distinct mutations or one mutation present at the homozygote state. For AD, we selected 66 candidate genes considering the dominant mode of inheritance. Given the phenotypic overlap between AD and GD, we also searched for a shared mutated gene among the five




Figure 1. Clinical and Radiological Features in GD and AD

(B, D, F, and G) GD patient 1 at 5 years and (A, C, and E) 15 years; note the “happy” face with full cheeks, a shortened nose, and a long and flat philtrum with a thin upper lip. (D and E) Note the delayed bone age and cone-shaped epiphyses, (F) shortened long tubular bones, epiphyseal dysplasia, and (G) ovoid vertebral bodies.

(H and I) AD patient 21 at 3 years and 62 years. Note the round face, bulbous nose, pseudomuscular build, (J, K, L, and M) very short hands and feet with a delayed bone age, and (N) the internal notch of the femoral head.

exomes. We identified changes in three genes: *MUC17* (MIM 608422), *HYDIN* (MIM 610812), and *FBN1*. The link between tall stature and Marfan syndrome caused by *FBN1* mutations (MIM 154700) prompted us to consider *FBN1* as the best candidate gene.⁹

Exome analysis detected three missense *FBN1* mutations (c.5096A>G [p.Tyr1699Cys], c.5087A>G [p.Tyr1696Cys], and c.1414T>C [p.Tyr472His]) in both GD patients and three heterozygous *FBN1* missense mutations (c.5182G>A [p.Ala1728Thr], c.5165C>G [p.Ser1722Cys], and c.5251T>G, [p.Ser1750Arg]) in AD patients. These results were confirmed by Sanger sequencing. However, Tyr472His was considered a polymorphism on the basis of information from the Marfan mutation database. *FBN1* screening led to the identification of six distinct heterozygous mutations in 17 additional GD cases. These mutations were not observed in GD parents, confirming that they occurred de novo.

Subsequent analyses in AD isolated seven *FBN1* mutations. In two out of ten AD cases, mutations were

identified in the affected parent, whereas they occurred de novo in the remaining cases. All mutations were absent from alleles in 2000 ethnicity-matched controls and in the Marfan mutation database.^{10,11} All together, we identified a total of 16 distinct heterozygous *FBN1* mutations in 29 GD and AD cases (15 missense and one insertion, Table 2). Importantly, all mutations were clustered in the same region (exons 41 and 42) encoding the TGFβ-binding protein-like 5 (TB5) domain of *FBN1* (Figure 2A).

Consequences of Mutations on 3D TB5 Domain Structure

We used homology modeling to investigate the distribution of sites affected by heterozygous GD and AD mutations within the structure of the TB5 domain (Figure 2B) by using the known crystal structure of fibrillin-1 fragment cbEGF22-TB4-cbEGF23 as a template.¹² GD substitutions appeared to alter structurally important residues such as cysteines involved in disulphide bond formation (Cys1706,

Table 2. *FBN1* Mutations Identified in Individuals with GD and AD

Family	Origin	Diagnosis	Nucleotide Change	Amino Acid Change	Parent Tested: De Novo Event Confirmed
1	Belgium	GD	c.5087A>G	p.Tyr1696Cys	yes
2	France	GD	c.5096A>G	p.Tyr1699Cys	yes
3	Russia	GD	c.5284G>A	p.Gly1762Ser	no mutation in the mother; father not available
4	Switzerland	GD	c.5096A>G	p.Tyr1699Cys	Parents not available
5	Russia	GD	c.5284G>A	p.Gly1762Ser	yes
6	France	GD	c.5284G>A	p.Gly1762Ser	yes
7	UK	GD	c.5087A>G	p.Tyr1696Cys	yes
8	Turkey	GD	c.5096A>G	p.Tyr1699Cys	no mutation in the mother; father not available
9	Algeria	GD	c.5117G>A	p.Cys1706Tyr	yes
10	Lebanon	GD	c.5157C>G	p.Cys1719Trp	yes
11	USA	GD	c.5096A>G	p.Tyr1699Cys	no
12	Turkey	GD	c.5284G>A	p.Gly1762Ser	yes
13	Russia	GD	c.5284G>A	p.Gly1762Ser	yes
14	Iraq	GD	c.5182G>A	p.Ala1728Thr	yes
15	USA	GD	c.5183C>T	p.Ala1728Val	yes
16	Japan	GD	c.5095T>G	p.Tyr1699Asp	yes
17	Australia	GD	c.5198G>A	p.Cys1733Tyr	yes
18	USA	GD	c.5284G>A	p.Gly1762Ser	no
19	Korea/Japan	GD	c.5096A>G	p.Tyr1699Cys	no mutation in the mother; father not available
20	France	AD	c.5182G>A	p.Ala1728Thr	yes
21	France	AD	c.5165C>G	p.Ser1722Cys	yes
22-a	France	AD	c.5251T>G	p.Ser1750Arg	inherited from 22-c
22-b	France	AD	c.5251T>G	p.Ser1750Arg	inherited from 22-c
22-c	France	AD	c.5251T>G	p.Ser1750Arg	yes
23	Belgium	AD	c.5177G>T	p.Gly1726Val	yes
24	Netherlands	AD	c.5096A>G	p.Tyr1699Cys	yes
25	France	AD	c.5202_5204dup	p.Gln1735dup	yes
26	Italy	AD	c.5273A>T	p.Asp1758Val	no
27-a	China	AD	c.5099A>G	p.Tyr1700Cys	inherited from 27-b
27-b	China	AD	c.5099A>G	p.Tyr1700Cys	yes
28	France	AD	c.5141T>G	p.Met1714Arg	yes
29	France	AD	c.5165C>G	p.Ser1722Cys	yes

Cys1719, Cys1733) or large aromatic components (Tyr1696, Tyr1699, Tyr1700). The GD substitutions were also clustered near the region of the TB domain known to be involved in intermolecular interactions on the basis of integrin-binding studies with fibrillin-1 TB4 domain fragments and LAP-LTBP interactions. AD substitutions appeared to be even more evenly distributed throughout the TB5 domain.

Microfibrillar Structure

To analyze the consequences of *FBN1* mutations, we compared the microfibrillar structure in skin fibroblasts

from GD and AD patients to that in control fibroblasts by indirect immunofluorescence. Staining revealed abundant long microfibrils in controls, but AD and GD fibroblasts demonstrated a reduced number of microfibrils and complete network disorganization (Figure 3A).

Analysis of TGF β Signaling Pathway

To test the impact of TB5 domain substitutions on TGF β signaling, we analyzed phospho-SMAD2 and -3 in the cell lysate of GD and AD fibroblasts and age- and passage-matched control skin fibroblasts by immunoblot




Figure 2. Location of *FBN1* Mutations Identified in GD and AD Patients

(A) Functional domains of *FBN1*. The location of the amino change found in each family is shown (GD are families listed in roman font; AD families are in italics, and mutations shared by AD and GD are in bold).

(B) 3D modeling of the fibrillin-1 cbEGF24-TB5-cbEGF25 region showing residues affected by GD and AD mutations. GD substitutions (I) are shown in magenta and AD substitution sites (II) are shown in cyan. Note the clustering of disease-causing substitutions in the region of the TB domain previously associated with protein-protein interactions. cbEGF domains are shown in green, and the TB domain is in blue. Red spheres represent calcium ions bound to domains cbEGF24 and cbEGF25. Homology modeling created with Modeler software⁷ and the coordinates of the fibrillin-1 cbEGF22-TB4-cbEGF23 structure (PDB 1UZJ). The figure was generated with Pymol. GD substitutions are shown in roman font, whereas those found in AD or in both diseases are shown in italics and bold, respectively.

(Figure 3B) and found an enhanced signal. Consistent with this observation, we quantified active and total TGF- β in the cultured medium of GD and AD skin fibroblasts by ELISA and found a 10-fold higher level of total TGF- β in the cultured medium of GD and AD fibroblasts than in the controls ($p < 0.0003$) (Figure 3C).

Link between *FBN1* and *ADAMTSL2*

Because we have previously identified *ADAMTSL2* mutations in a subset of GD patients, we hypothesized a direct link between *FBN1*, which is involved in AD and a portion of GD patients, and *ADAMTSL2*. To demonstrate this interaction, we performed surface plasmon resonance analysis by using *FBN1* recombinant protein.

Although the fibrillin construct used did not contain TB5 domain, this analysis identified a specific direct interaction ($K_D = 60$ nM) between the two proteins (Figure 4).

Discussion

Here, we report the identification of *FBN1* mutations in 19 GD and ten AD patients; both GD and AD are clinically defined conditions combining short stature, short hands, and stiff joints.

Although GD has been described as an autosomal-recessive disorder, the identification of heterozygous *FBN1* mutations demonstrates a dominant form of GD, strictly fulfilling the diagnostic criteria for GD (including progressive cardiac valvular thickening and early death in three out of 19 GD patients without *ADAMTSL2* mutations). As previously reported,⁵ we did not find any significant difference in the main clinical and radiological features characteristic of GD, namely cardio-respiratory involvement, skin thickness, facial features (including a round full face, a small nose with anteverted nostrils, and a long philtrum) hepatomegaly, natural history of the disorder, and severe outcome between the two forms of GD. However, a broad nasal bridge, narrow palpebral fissures, and tip-toe walking were more consistently observed in the *ADAMTSL2*-mutated group.⁵ These minor phenotypic differences between the two forms of GD might guide the clinician diagnostically and help in the prioritization of the molecular screening.

Similarly, all AD cases fulfilled the diagnostic criteria of AD. None of them had cardiac involvement or early death. These data demonstrate that GD and AD appear clinically distinct but are allelic conditions.

We did not find any obvious differences in the nature of the mutations identified in GD compared to the mutations identified in AD. Among the 16 *FBN1* mutations identified,




Figure 3. Microfibril and TGF β -Signaling Analysis in GD and AD Skin Fibroblasts

(A) Microfibrillar analysis in skin fibroblasts from (a) control, (b) a GD patient, and (c) an AD patient. The microfibrillar network formation was detected by indirect immunofluorescence with fibrillin-1 antibody. (MAB019). The staining revealed abundant long microfibrils in the control fibroblasts (a). Conversely, the GD and AD patient fibroblasts showed a reduced number of microfibrils and a disorganization of the MF network (b and c). The scale bar represents 50 μ m.

(B) Enhanced phosphorylation of SMAD2 (pSMAD2) in skin fibroblasts from one GD patient (family 8), one AD patient (family 22), and control. pSMAD2 was normalized to actin for comparison of pSMAD2 levels in affected and unaffected fibroblasts as shown in the right panel.

(C) Quantification of total (gray bars) and active (black bars) TGF β in the conditioned medium of fibroblasts from individuals with GD (family 8) or AD (family 22) and controls. The conditioned medium from families 8 and 22 showed an amount of total TGF β (* $p < 0,003$) greater than the conditioned medium from the controls.

seven were specifically identified in GD and seven were specifically identified in AD, but two mutations were found in either GD or AD cases. All mutations were located in exons 41 and 42, encoding the TB5 domain and were altering either large aromatic components or structurally important residues. Half of the mutations were creating or removing a cysteine residue within this domain, which is characterized, as are the other TB domains, by eight cysteines directly involved in FBN1 folding via intradomain disulfide linkage.¹³

Although *FBN1* mutations have been identified in a wide range of disorders from Marfan syndrome to isolated ectopia

lentis, our findings support that mutations of the TB5 domain are responsible for the phenotype of short stature, short hands, and stiff joints. A deletion in TB5 domain has been previously reported in Weill-Marchesani syndrome [MIM 608328], which is also characterized by short stature, short hands, and stiff joints but differs from AD and GD in the presence of microspherophakia.¹⁴ More recently, mutations in the TB4 domain have been reported in stiff skin [MIM 184900] patients, who differ from AD and GD by the absence of short stature and short hands.¹⁵

It is not known why mutations affecting the TB5 domain give rise to GD and AD rather than Marfan syndrome. Our




Figure 4. ADAMTSL2 Interacts Directly with Fibrillin-1

(A) The domain structure of the fibrillin peptide hFib1-49 is shown relative to the full-length fibrillin-1. The key to the fibrillin-1 modules is shown.

(B) Colloidal Coomassie-blue-stained-reducing polyacrylamide gel showing purification of hFib1-49 (arrow). The molecular weight markers (in kDa) are indicated on the left.

(C) SPR analysis of ADAMTSL2 (analyte) binding to hFib1-49 (ligand). The sensorgrams shown were obtained after injection of increasing concentrations of ADAMTSL2 as indicated. The y axis indicates the response difference obtained between the flow cell with bound hFib1-49 and the control flow cell without hFib1-49 when ADAMTSL2 was used as the analyte. The x axis shows time (s).

findings of a specific interaction between FBN1 and ADAMTSL2 might support the hypothesis that a dysregulation of FBN1/ADAMTSL2/TGF β interrelationship is the underlying mechanism of the short stature phenotypes. The finding of similar enhancement of TGF β signaling and microfibrillar structural changes in AD and GD with FBN1 or ADAMTSL2 mutations further supports the functional link between the TB5 domain and ADAMTSL2.

However, the finding of increased TGF β signaling in fibroblasts from AD and GD and Marfan patients is still questionable and further illustrates the tissue dependence and the complexity of the TGF β - and SMAD-signaling pathways with various levels of regulations. We hope that ongoing studies will document interaction of TB5 domain and ADAMTSL2 and contribute to a greater understanding of how enhanced TGF β signaling caused by FBN1 mutations can trigger either tall stature, arachnodactyly, and hyperlaxity or severe short stature, short hands, and stiff joints.

Acknowledgments

We thank all the patients and their families for their contribution to this work. The work presented here was supported by the Medical Research Foundation (FRM to S.A.), a French National Research Agency (ANR) award (R09183KS to V.C.-D.), and a National Institutes of Health-National Institute of Arthritis and Musculoskeletal Skin Diseases grant (AR53890 to S.S.A.). B.Z. is supported by the German Federal Ministry of Education and Research (BMBF, SKELNET project).

Received: April 6, 2011

Revised: May 10, 2011

Accepted: May 12, 2011

Published online: June 16, 2011

Web Resources

The URLs for data presented herein are as follows:

Marfan Mutation Database, <http://www.umd.be/>

Mutation Nomenclature, <http://www.hgvs.org/mutnomen>

Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org>

Pymol, <http://www.pymol.org>

References

- Spranger, J.W., Gilbert, E.F., Tuffli, G.A., Rossiter, F.P., and Opitz, J.M. (1971). Geleophysic dwarfism—a “focal” mucopolysaccharidosis? *Lancet* 2, 97–98.
- Maroteaux, P., Stanescu, R., Stanescu, V., and Rappaport, R. (1986). Acromicric dysplasia. *Am. J. Med. Genet.* 24, 447–459.
- Faivre, L., Le Merrer, M., Baumann, C., Polak, M., Chatelain, P., Sulmont, V., Cousin, J., Bost, M., Cordier, M.P., Zackai, E., et al. (2001). Acromicric dysplasia: Long term outcome and evidence of autosomal dominant inheritance. *J. Med. Genet.* 38, 745–749.
- Le Goff, C., Morice-Picard, F., Dagoneau, N., Wang, L.W., Perrot, C., Crow, Y.J., Bauer, F., Flori, E., Prost-Squarcioni, C., Krakow, D., et al. (2008). ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. *Nat. Genet.* 40, 1119–1123.
- Allali, S., Le Goff, C., Pressac-Diebold, I., Pfennig, G., Mahaut, C., Dagoneau, N., Alanay, Y., Brady, A.F., Crow, Y.J., Devriendt, K., et al. (2011). Molecular screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of geleophysic dysplasia. *J. Med. Genet.* 48, 417–421.
- Kettle, S., Card, C.M., Hutchinson, S., Sykes, B., and Handford, P.A. (2000). Characterisation of fibrillin-1 cDNA clones in a human fibroblast cell line that assembles microfibrils. *Int. J. Biochem. Cell Biol.* 32, 201–214.
- Hirohata, S., Wang, L.W., Miyagi, M., Yan, L., Seldin, M.F., Keene, D.R., Crabb, J.W., and Apte, S.S. (2002). Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular matrix. *J. Biol. Chem.* 277, 12182–12189.
- Eswar, N., Webb, B., Marti-Renom, M.A., Madhusudhan, M.S., Eramian, D., Shen, M.Y., Pieper, U., and Sali, A. (2007). Comparative protein structure modeling using MODELLER. *Curr. Protoc. Protein Sci.* Chapter 2:Unit 2.9.
- Dietz, H.C., Cutting, G.R., Pyeritz, R.E., Maslen, C.L., Sakai, L.Y., Corson, G.M., Puffenberger, E.G., Hamosh, A., Nanthakumar, E.J., Curristin, S.M., et al. (1991). Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. *Nature* 352, 337–339.
- Frédéric, M.Y., Lalande, M., Boileau, C., Hamroun, D., Claustres, M., Bérout, C., and Collod-Bérout, G. (2009). UMD-predictor, a new prediction tool for nucleotide substitution pathogenicity — application to four genes: FBN1, FBN2, TGFBR1, and TGFBR2. *Hum. Mutat.* 30, 952–959.
- Collod-Bérout, G., Le Bourdelles, S., Ades, L., Ala-Kokko, L., Booms, P., Boxer, M., Child, A., Comeglio, P., De Paepe, A., Hyland, J.C., et al. (2003). Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. *Hum. Mutat.* 22, 199–208.
- Lee, S.S., Knott, V., Jovanović, J., Harlos, K., Grimes, J.M., Choulier, L., Mardon, H.J., Stuart, D.I., and Handford, P.A. (2004). Structure of the integrin binding fragment from fibrillin-1 gives new insights into microfibril organization. *Structure* 12, 717–729.
- Yuan, X., Downing, A.K., Knott, V., and Handford, P.A. (1997). Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils. *EMBO J.* 16, 6659–6666.
- Faivre, L., Gorlin, R.J., Wirtz, M.K., Godfrey, M., Dagoneau, N., Samples, J.R., Le Merrer, M., Collod-Beroud, G., Boileau, C., Munnich, A., and Cormier-Daire, V. (2003). In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. *J. Med. Genet.* 40, 34–36.
- Loeys, B.L., Gerber, E.E., Riegert-Johnson, D., Iqbal, S., White-man, P., McConnell, V., Chillakuri, C.R., Macaya, D., Coucke, P.J., De Paepe, A., et al. (2010). Mutations in fibrillin-1 cause congenital scleroderma: Stiff skin syndrome. *Sci. Transl. Med.* 2, ra20.